Integrins (ITGs) are mediators of cell-cell and cell-matrix interactions, which are also associated with embryo implantation processes by controlling the interaction of blastocyst with endometrium. During early pregnancy, ITGbeta8 (ITGB8) has been shown to interact with latent transforming growth factor (TGF) beta 1 (TGFB1) at the fetomaternal interface. However, the precise role of ITGB8 in the uterus and its association with embryo implantation has not been elucidated. Therefore, we attempted to ascertain the role of ITGB8 during the window of embryo implantation process by inhibiting its function or protein expression. Uterine plasma membrane-anchored ITGB8 was augmented at peri-implantation and postimplantation stages. A similar pattern of mRNA expression was also found during the embryo implantation period. An immunolocalization study revealed the presence of ITGB8 on luminal epithelial cells along with mild expression on the stromal cells throughout the implantation period studied; however, an intense fluorescence was noted only during the peri-and postimplantation stages. Bioneutralization and mRNA silencing of the uterine Itgb8 at preimplantation stage reduced the rate/ frequency of embryo implantation and subsequent pregnancy, suggesting its indispensable role during the embryo implantation period. ITGB8 can also regulate the liberation of active TGFB1 from its latent complex, which, in turn, acts on SMAD2/ 3 phosphorylation (activation) in the uterus during embryo implantation. This indicates involvement of ITGB8 in the embryo implantation process through regulation of activation of TGFB1.
INTRODUCTION
Successful implantation of embryo necessitates a receptive endometrium and functional blastocyst, which happens during a restricted period defined as the window/period of embryo implantation, leading to a synchronized two-way dialogue between blastocyst and maternal endometrium [1] . The implantation process of embryo/blastocyst involves several distinct steps, including adhesion and trophoblast invasion [2, 3] . Previous reports have suggested highly coordinated expression and activation of cell adhesion molecules during the process of embryo implantation [4] . The family of adhesion molecule includes integrin beta (ITGB) 8 as one of the important members. During embryo implantation, interaction between the blastocyst and maternal uterine luminal linings is regulated through integrins (ITGs) [5, 6] , where the ITGs ALPHA1BETA1, ALPHA4BETA1, and ALPHAVBETA3 are key to the formation of the putative window of endometrial receptivity [7] . ITG ALPHAVBETA3 is present on the surface of endometrial luminal epithelium, which initially interacts with trophoblast [8] .
During embryo implantation, the apposition step involves adherence of trophoblast cells to a receptive epithelium of the endometrium [9] . ITGs play a crucial role in interactions with extracellular matrix (ECM) to transduce cellular signals between uterine epithelial cells and trophoblast cells of implanting embryo [10] .
Endometrial ITGs involved in the attachment with blastocyst include ALPHAV ITGs, which heterodimerize with beta polypeptides of ITG, and ITGB8 is one of the binding partners of ALPHAV [11] . ITGB8 binds with the Vitronectin and Fibronectin receptors (ECM components) that are associated with the process of embryo implantation as well [12] . Embryos with mutation in ITGB8 die at Day 10 of the embryonic stage due to lack of vascular development in the yolk [13] . Furthermore, a recent report has postulated the interaction of ITGB8 with transforming growth factor beta (TGFB) at the fetomaternal interface during pregnancy [14] , as ITGB8 can transduce signaling through TGFB [15] . It is widely accepted that TGFB is produced as a latent inactive complex (i.e., large and small) [16] . Recently, we reported that the biologically active form of TGFB (monomer and homodimer) in the uterus assists in the process of embryo implantation [17] . ITGB8 is a receptor for the inactive latent TGFB-associated peptide (LAP), and can mediate the availability of biologically active TGFB [11] . ITGB8 activates TGFB1 by recognizing the tripeptide sequence arginine-glycine-aspartate present in LAP of TGFB1 latent complex [18] . ITGB8 can also regulate vascular morphogenesis either through the activation of TGFB or vascular endothelial growth factor [19] . Similar types of mechanisms might also be present at the fetomaternal interface [20] that bring about the vascular development in the embryo (E10) [13] .
However, the exact mechanism of action of ITGB8 in the uterus during embryo implantation is not known. Hence, in the present study, we elucidate the possible involvement of uterine ITGB8 during embryo implantation using a mouse model of pregnancy. We have also analyzed TGFB1 activation via ITGB8 signaling in the uterus during the embryo implantation process. 
MATERIALS AND METHODS
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Mouse Model of Pregnancy
All animal experiments were performed according to guidelines of the local Institutional Animal Ethics Committee (IAEC) at CSIR-CDRI, Lucknow, India (IAEC approval #IAEC/2014/10, dated 7 February 2014). Sexually mature virgin female mice (Swiss albino, 3-4 mo old) were cohabitated with males of proven fertility. Success in insemination was confirmed by the presence of whitish vaginal plug on the following morning and assigned as Day 1 postcoitus (p.c.) of the pregnancy, as described previously [17, 21] . Uterine tissues were collected from animals at different time points of window of embryo implantation (i.e., . A minimum of three to five replicates (individuals) were used in each stage/group of the embryo implantation period. Implantation and nonimplantation sites in the uterus were visualized with the help of Evans Blue dye (0.1%) injection, as reported previously [22] . The embryos were recovered through gentle flushing of each uterine horn to verify the implantation stages and uterine tissue was processed separately for extraction of crude plasma membranous protein fraction. Embryos were also processed for immunofluorescence study.
Immunofluorescence Study of Embryo
Immunofluorescence studies were carried out as described previously with slight modifications [22] . Briefly, embryos (n ¼ 5) were fixed in 4% paraformaldehyde (PFA) prepared in PBS for 60 min at room temperature. The overreaction of PFA was neutralized by incubation of embryos with 50 mM NH 4 Cl, and permeabilization was accomplished with 0.3% Triton-X 100 in PBS for 20 min. Blastocysts were then blocked in PBS containing 0.5% bovine serum albumin (BSA) for 60 min and incubated with anti-ITGB8 (1:100 dilution) overnight at 48C followed by incubation with anti-rabbit IgG (Oregon green 488; 1:200 dilution) for 2 h in the dark at room temperature. DAPI (1 lg/ml) was used for the nuclear staining. All experiments were performed at least three times and observations were made under a Nikon ECLIPSE-80I microscope. The images were captured by MOTICAM-580 5.0-megapixel camera (Motic, Hong Kong).
Immunofluorescence Microscopy of Uterine Tissue
For immunofluorescence studies on uterus, tissues samples were dehydrated, cleared in xylene, embedded in paraffin wax, and sectioned (5 lm) using a microtome (RM2125RT; Leica, Germany). Thereafter, sections were deparaffinized in xylene, rehydrated, and rinsed in PBS. Slides were autoclaved for 10 min after placing them in a coupling jar with sodium citrate buffer (pH 6.0). After cooling at room temperature, slides were rinsed in PBS and incubated with blocking solution (1% BSA) for 1 h and, thereafter, incubated overnight with anti-ITGB8 antibody (1:50 dilution). Immunofluorescence labeling was performed using anti-rabbit IgG conjugated with fluorescein isothiocyanate (FITC) and counterstained with DAPI (1 lg/ml) for nuclear staining [22] . The sections were observed under a Nikon ECLIPSE-80I microscope and images were captured by MOTICAM-580 5.0 megapixel camera. Immunofluorescence patterns of ITGB8 were then analyzed, taking into account the localization along with the intensity. Four consecutive sections from each of the uterine horns were used for this study. Experiments were repeated at least three times (n ¼ 3).
Bioneutralization of ITGB8
Pregnant females underwent minilaparotomy under anesthesia at Day 4 (1000 h) of the window of embryo implantation to deliver the ITGB8 antibody (5 ll of 1.5 lg; cat. #25714; Santa Cruz Biotechnology, Inc.) in one of the horns, while the other horn of the same animal (control) received 1.5 lg normal rabbit IgG, as described elsewhere [23] . The ITGB8 antibody has been previously validated by Massuto et al. [14] . One group of ITGB8 IgG-treated females (n ¼ 7) was used for the study of embryo implantation sites during Postimplantation Stage Day 5 (1000 h). A second group of ITGB8 IgG-treated females (n ¼ 5) was taken for the fetus development analysis study at Day 13 p.c. [24] . Treated and untreated animals were killed and their uteri were photographed to record the number of implanted embryos.
Treatment of Pregnant Mice with Morpholino Antisense Oligonucleotide
Pregnant females underwent minilaparotomy as described previously [25] on Day 4 (1000 h) (n ¼ 7). The left uterine horn of mice was injected with 2 ll (30 nM) of Morpholino oligonucleotide (MO) against Itgb8 into the lumen of one uterine horn through the oviductal site, while the right horn was injected with control MO (30 nM), as described elsewhere [24] . Implantation sites and inter-/nonimplantation sites in the uterus were visualized as in a previously described method [17] .
Plasma Membrane Protein Extract Preparation
Protein was extracted from the whole uterus. Implantation and nonimplantation sites in the uterus at different stages were processed separately. Briefly, uterine tissue was minced properly in homogenizing buffer containing 100 mM KCl, 3 mM NaCl, 3.5 mM MgCl 2 , 10 mM PIPES, 1.5 mM ethyleneglycol-bis-(b-aminoethyl ether)-N,N 0 -tetraacetic acid, phosphatase inhibitor cocktail and protease inhibitor cocktail (pH 7.4) as described previously [17] . Homogenized tissue suspension was centrifuged at 200 3 g and 48C to pellet out unbroken cells. Supernatant was again centrifuged at 1470 3 g for 10 min at 48C to separate nuclei. Postnuclear supernatant was further centrifuged (48C) at 12 000 3 g for 10 min to collect crude plasma membranous protein extract, and stored at À808C for further analysis.
Immunoprecipitation Assay
Protein extracts (crude plasma membranous fraction) from different stages (n ¼ 7) of pregnancy were precleared with protein A-agarose as described previously [17, 26] . Precleared protein extract (100 lg) was further incubated overnight either with 1 lg of anti-ITGB8 or TGFB1 at 48C. The protein A-agarose was washed with PBS, and 50% slurry of protein A-agarose was prepared in the membrane protein isolation buffers. The immune complexes were captured by addition of protein A-agarose 15 ll/lg antibody for 2 h at 48C. Thereafter, protein (immunoprecipitation [IP]) samples were resolved on 10-12% SDS-PAGE and subjected to Western blotting.
SDS-PAGE and Western Blotting
The concentration of the uterine protein extracts were estimated through Bio-Rad Protein Assay kit. Proteins were denatured with Laemmli buffer [27] containing b-mercaptoethanol. Proteins (20 lg) were separated by 12% SDS-PAGE in native (nondenatured) condition and 7.5% or 10% SDS-PAGE under the denatured condition [28] . Blotted membranes were blocked in 5% nonfat KUMAR ET AL. milk for 2 h followed by incubation with respective primary antibodies against ITGB8 (dilution, 1:1000), ITGB3 (dilution, 1:1000), TGF-B1 (dilution, 1:500), SMAD2/3 (dilution, 1:1000), p-SMAD2/3 (dilution, 1:1000), STAT3 (dilution, 1:200), p-STAT3 (dilution, 1:200), and b-actin (dilution, 1:8000) overnight at 48C temperature. Subsequently, membranes were probed with respective secondary antibodies (anti-rabbit IgG or anti-mouse IgG HRP) in 1:3000 dilution. The ITGB8, STAT3, and TGF-B1 antibodies have already been validated [14, 17, 29, 30] . Immunoreactive bands were visualized through ECL exposure according to the manufacturer's protocol. Immunoblots were imaged by ImageQuant LAS 4000 gel documentation system (GE Life Sciences) and band intensity was analyzed by TotalLab Quant (Nonlinear Dynamics, Newcastle-upon-Tyne, UK).
Total Uterine RNA Extraction, First-Strand cDNA Synthesis, and PCR Total RNA was isolated from uterine tissue (n ¼ 3 in each stage/group) of the embryo implantation period using TRI-ZOL reagent (Sigma-Aldrich), according to the manufacturer's protocol. The concentration of RNA was measured by using Nanodrop (Thermo Fisher Scientific, Wilmington, DE). First-strand of DNA (cDNA) was prepared from total RNA (1 lg) of each stage of pregnancy by reverse transcription using a Superscript first-strand cDNA synthesis kit (Invitrogen BioServices India Pvt. Ltd., Bangalore, India), according to the manufacturer's protocol. PCR reactions were then performed with 1 ll of cDNA, 10 ll of PCR Master mix (Invitrogen BioServices India Pvt. Ltd.), and 1 ll of Itgb8 gene primer pair. Partial gene product amplification was carried out for 35 cycles, and each cycle consisted of denaturation (5 min at 948C), annealing (30 sec at 588C), and extension (30 sec at 728C) steps. PCR products were resolved on a 2% agarose gel prestained with ethidium bromide (10 mg/ml). Band densities of PCR products in the agarose gel were scanned with a Gel Doc imaging system (ImageQuant LAS 4000 gel documentation system; GE-healthcare, Pittsburgh, PA), and quantified by Totallab Quant Software (Nonlinear Dynamics).
Statistical Analysis
Experiments were performed at least three times with 7 animals per group (n¼ 7). Protein band intensities were averaged and the SEM values were calculated. Group comparisons were made by one-way ANOVA followed by the Turkey test employing GraphPad Prism 5 software. P values , 0.05 among different groups were considered significant; b-actin was used as a loading control.
RESULTS
Expression of ITGB8 Increases at Implantation Sites of the Peri-Implantation Stage During the Window of Embryo Implantation
ITGs are known to be involved in uterine remodeling during embryo implantation [31, 32] . Thus, we examined the association of ITGB8 in embryo implantation. Our Western blot analysis revealed the presence of ITGB8 in uterine plasma membrane and cytosol compartmental protein of all the stages of window/period of embryo implantation (Fig. 1,  A and B) . Preimplantation stage showed a lower level of ITGB8 expression, which increased significantly (P , 0.05) at Day 4 (1600 h) and culminated at Day 5 (0500 h), and this high expression level was maintained until Day 5 (1000 h) (Fig. 1, A and B) of the embryo implantation period. ITGB8 was prominent at the implantation sites at both 0500 h and 1000 h on Day 5 of the embryo implantation than that of their respective nonimplantation sites (P , 0.05; Fig. 1,  A and B) .
To verify the mRNA expression of Itgb8 in the uterus, we determined its transcript level during the embryo implantation period. Our study revealed a low level of Itgb8 transcript at Day 4 (1000 h), which was subsequently elevated at the late preimplantation stage (Day 4, 1600 h) (Fig. 1, C and D) . The expression level of Itgb8 transcript was further increased at implantation sites of peri-implantation (Day 5, 0500 h) and postimplantation (Day 5, 1000 h) stages of pregnancy (Fig. 1, C and D) .
Immunocytochemical Analysis of ITGB8 Localization During the Window of Embryo Implantation
ITGB8 was seen predominantly on uterine epithelial cells and mildly in the glandular epithelial cells, and, to a certain extent, on the stromal cells (Fig. 2) . Epithelial cells displayed stronger signal on the apical and basal sites than the adjacent cells during peri-and postimplantation stages (Fig. 2) . The fluorescence signal intensity of ITGB8 was comparatively low in pre-and late preimplantation stages of pregnancy, which increased at the implantation site of peri-and postimplantation stages. Negative control, without primary antibody incubation, did not result in any detectable levels of fluorescence signals (Fig. 2) .
Immunolocalization of ITGB8 in Blastocyst of Mice During Different Stages of the Implantation Period
Results of immunolocalization study showed expression of ITGB8 throughout the stages of embryonic development (Fig.  3) . Fluorescence intensity of ITGB8 was markedly increased at the time of implantation at Day 5 (0500 h) and Day 5 (1000 h), but had moderate fluorescence at Day 4 (1600 h) (Fig. 3) . Furthermore, fluorescence was localized at the inner cellular mass (ICM) during Day 5 (0500 h). At the subsequent stage (Day 5, 1000 h), it was seen distributed in the entire cell population of the embryo. Rabbit IgG as a control showed no detectable immunofluorescence (Fig. 3) .
Effect of ITGB8 Inhibition on Embryo Implantation
Functional blockage of ITGB8 can reduce embryo implantation. Since the expression of ITGB8 was predominant at implantation sites of the peri-and postimplantation stages, we further assessed the functional role of ITGB8 in the process of embryo implantation.
Administration of anti-ITGB8 antibody at Day 4 (1000 h) p.c. in the uterine horn lumen reduced pregnancy effectively (fetus/embryo number) at Day 13 (P , 0.04) and the anti-ITGB8-treated uterine horn showed only one embryo (1.0 6 1.0 [mean 6 SD]), whereas the control uterine horn exhibited 4 embryos (4.0 6 2.0) (Fig. 4, A and B) . There was no apparent effect of normal rabbit IgG isotype on the implantation rate in the same-animal uterine horn (sham/control). The composition of anti-ITGB8 rabbit IgG and normal rabbit IgG suspension was the same, which further confirmed the effect was mediated by ITGB8.
Next, we determined the immediate effect of ITGB8 bioneutralization on embryo implantation at the Postimplantation Day 5 (1000 h) stage. The delivery of anti-ITGB8 IgG in the uterine lumen during preimplantation stage reduced the numbers of embryos present (0.75 6 0.95; P , 0.02; Fig. 4D ), whereas the control uterine horn (normal rabbit IgG treated) showed no effect on the morphological appearance and development of embryo (2.75 6 1.25) at Day 5 (1000 h) (Fig. 4C) . In addition, anti-ITGB8-administered uteri exhibited only 17.6% implantation sites than the normal rabbit IgG isotype (P , 0.001; Fig. 4, E and F) .
We further confirmed the neutralizing efficiency of ITGB8 by immunofluorescence, and our results showed the presence of ITGB8 on uterine epithelial cells and milder expression on glandular epithelial cells of ITGB8-treated and control antibody groups. The signal intensity of ITGB8 was enhanced at the apical region of uterine epithelial cells. Stromal cells showed a mild expression level of ITGB8 in both groups (Supplemental Fig. S1 ; Supplemental Data are available online at www.biolreprod.org).
ITGB8 ACTIVATES TGFB1 IN UTERUS
Inhibition of ITGB8 mRNA/protein expression at the preimplantation stage can interfere with embryo implantation. Attenuation of Itgb8 mRNA by intrauterine administration of its antisense MO demonstrated a ;62% reduction in the numbers of sites of blastocyst implantation (P , 0.05) (Fig. 5,  A and B) . Thereafter, we observed recovered blastocyst numbers from these Itgb8 MO-and control MO-treated mouse uteri. Itgb8 MO-treated uteri showed lower numbers of blastocysts (1.3 6 1.2; 37%) than the control MO-treated uteri (3.5 6 1.5) (P , 0.001; Fig. 5, C and D) , and their morphologies were disrupted, unlike the postimplantation embryo (Fig. 5C) . 
We also examined the protein expression levels of Itgb8 in its antisense MO-treated uterine cytosolic plus plasma membrane fraction of implantation and non-/interimplantation sites using Western blotting (Fig. 5, E and F) . The expression level of Itgb8 was decreased in the implantation sites of the Itgb8 antisense MO-treated group compared with the control uterine group (P , 0.01; Fig. 5, E and F) . There was an ;67 % reduction in the expression of ITGB8 in implantation sites of its antisense MOtreated group when compared with the control MO group. In addition, we also observed low levels of ITGB8 expression (P , 0.01) in the nonimplantation sites of the Itgb8 MO-treated uterine group compared with that of implantation sites of the control MO group (Fig. 5, E and F) . We did not find a significant reduction of ITGB8 protein in the nonimplantation sites of the control MO group with respect to its corresponding implantation sites.
ITGB8 Can Regulate the Embryo Implantation-Related Genes
Inhibition of ITGB8 showed reduced expression of embryo implantation-related biochemical markers ITGB3, STAT3, and BMP2. ITGB3 and STAT3 are well-known biochemical markers for embryo implantation endometrial receptivity; hence, we studied their expression profiles in response to ITGB8 inhibition. Total STAT3 exhibited significantly reduced expression levels in the ITGB8 antibody-treated group in comparison to the control antibody implantation group (P , 0.01; Fig. 6, A and B) . The ITGB8 antibody-treated group also showed reduced levels of phospho-STAT3 (Ser-727) in comparison to the control antibody implantation group (P , 0.05; Fig. 6, C and D) .
To check if cellular expression or distribution pattern of STAT3 is affected in response to ITGB8 treatment, we performed an immunofluorescence study in ITGB8 antibodyand control antibody-treated groups at the Day 5 (1000 h) stage of the embryo implantation period. Our results show the presence of STAT3 on uterine luminal epithelial cells and stromal cells; however, the fluorescence intensity was strong on luminal epithelial cells, with occasional presence on stromal cells in the control antibody group (Supplemental Fig. S2 ). Glandular epithelial cells showed mild expression of STAT3 in the control antibody group (Supplemental Fig. S2 ). The signal intensity of STAT3 was found to be reduced in the ITGB8 antibody-treated uterine tissue group when compared to the normal rabbit IgG-treated group (Supplemental Fig. S2 ). There was no detectable fluorescence signal when uterine tissue sections were incubated with anti-rabbit IgG FITC-conjugated antibody alone.
Furthermore, the expression level of total STAT3 was reduced (but not significantly so) in Itgb8 MO-treated implantation sites when compared with the control MO group (Fig. 6, E and F) . Our results show that the expression level of active or phosphorylated STAT3 (Ser-727) was significantly reduced in Itgb8 MO-treated implantation sites compared with that of control MO implantation sites (P , 0.01; Fig. 6 , G and H). We also analyzed the expression level of the embryo implantation/uterine receptivity-related biochemical marker, ITGB3, in response to intervention of ITGB8. The ITGB8 antibody-treated uterine group also showed reduced expression level of ITGB3 when compared to control antibody implantation sites (P , 0.05; Fig. 7, A and B) . Compared to the control MO implantation sites, ITGB3 expression level was significantly decreased in Itgb8 MO-treated implantation sites (P , 0.05; Fig. 7, C and D) , whereas nonimplantation sites showed no significant change with respect to the control (implantation sites) group (Fig. 7, C and D) .
Another embryo implantation gene, Bmp2 [33] , was also studied in the ITGB8 inhibition/neutralization group. Expression of Bmp2 transcript was found to be reduced in the ITGB8-treated group compared with the control group (Fig. 7, E and  F) . In the Itgb8 MO group, the implantation sites showed significantly decreased levels of Bmp2 gene transcript when compared to control MO implantation sites (Fig. 7, G and H) . Nonimplantation sites of the Itgb8 MO group also exhibited significantly low levels of Bmp2 compared to control nonimplantation sites.
Effect of ITGB8 Inhibition on Its Downstream Molecules
Bioneutralization and transient knockdown of uterine ITGB8 can block activation of TGF-B1 during embryo 
FIG. 4. Functional inhibition of ITGB8 can block embryo implantation. ITGB8 bioneutralization was assessed at the Day 13 p.c. stage (A and B) (n ¼ 5).
The effect of ITGB8 functional blockage on the development of blastocyst was also determined at Day 5 (1000 h) (C and D). Furthermore, the sites of embryo implantation were evaluated at Day 5 (1000 h) after bioneutralization of ITGB8 at Day 4 (1000 h) (E and F) (n ¼ 7). **P , 0.01,*P , 0.05). A and E shows images (macrographs) were acquired by Sony digital camera (model DCS-W160; 12 megapixels), whereas C shows a microscopic image (model TS-100F LED; Nikon, Japan) and obtained under the 103 magnification. Arrows indicate the fetus. D) were analyzed using immunoblotting and densitometry in the cytosol þ plasma membrane fraction of ITGB8-bioneutralized uterine tissue. Expression of STAT3 (E and F) and pSTAT3 (ser727) (G and H) was analyzed using immunoblotting and densitometry in the cytosol þ plasma membrane protein fraction of Itgb8 MO-treated uterine tissue. (n ¼ 7). b-Actin was utilized as a gel loading control, which was used to normalize the ITGB8 densitometric values. Data are presented as the mean 6 SEM. **P , 0.01, *P , 0.05, not significant (NS), P . 0.05.
ITGB8 ACTIVATES TGFB1 IN UTERUS
FIG. 7. Analysis of ITGB3 and BMP2 expression in the ITGB8-bioneutraled and MO-treated uterus. The expression of pregnancy marker ITGB3 was analyzed in ITGB8 IgG-treated (A and B) and Itgb8 MO-inhibited (C and D) uterus. The level of Bmp2 mRNA was also analyzed by RT-PCR in ITGB8 IgG-(E and F) and in Itgb8 MO-treated (G and H) uterus (n ¼ 7). b-actin was used as gel loading and normalizing control. ***P , 0.001, **P , 0.01, *P , 0.05, not significant (NS), P . 0.05. FIG. 8 . Analysis of TGFB1 activity in response to ITGB8 bioneutralization and knockdown. Native/nondenatured blotting of TGFB1 was done in the uterine protein extract (Day 5, 1000 h) in response to the ITGB8 functional blockage (A and B) and Itgb8 MO treatment (C and D) at Day 4 (1000 h) (n ¼ 7). Anti-LAP displayed LLC, SLC, and pro-TGFB1 protein bands in the presence and absence of ITGB8 bioneutralization (E). Similarly, anti-LAP recognized latent TGFB1 complexes LLC, SLC, and pro-TGFB1 in the Itgb8 MO treatment group (F). Secondary antibody alone did not cross-react with the anti-LAPrecognized bands; hence, this suggests the specificity of primary antibody (G) (n ¼ 7). ** P , 0.01,*P , 0.05, not significant (NS), P . 0.05. implantation. We further analyzed the activation of downstream signaling of ITGB8 at Day 5 (1000 h) after its bioneutralization at the preimplantation stage of the window of embryo implantation. This particular experiment also confirmed the bioneutralizing capability of anti-ITGB8 rabbit IgG. ITGB8 can activate TGFB for its biological function by liberating it from the large latent complex (LLC) TGFB or small latent complex (SLC) TGFB [11, 15] . We observed biologically active TGFB1 (;17 kDa) monomer on nonreducing immunoblot of uterine crude plasma membrane protein fraction in the control rabbit IgG group implantation sites, whereas the anti-ITGB8 IgG-treated group showed decreased active TGFB1 form (P , 0.05; Fig. 8, A and B) . The nonimplantation sites of the control group also had reduced active TGFB1 (P , 0.01; Fig. 8, A and B ) when compared to implantation sites. Interestingly, in addition, we also observed the predicted LLC (;220 kDa) and SLC (;75 kDa) of TGFB1 in the crude plasma membrane protein compartment, but LLC remained unaltered and SLC was undetectable in the ITGB8-inhibited group (Fig. 8A) .
In another set of experiment using Itgb8 MO, the activation (release of mature form; monomer ;17 kDa) of TGFB1 was also reduced significantly at implantation sites in Itgb8 MOtreated uterine horn (P , 0.01; Fig. 8 , C and D) as compared to control. The expression of SLC detected by TGFB1 did not show a significant difference at implantation sites in the Itgb8 MO-treated and control groups (Fig. 8C) . The nonimplantation sites of both the Itgb8 MO and control groups were devoid of SLC (Fig. 8C) .
We also cross-checked the latent complexes of TGFB1 using LAP antibody. Our results showed the presence of LLC, SLC, and additionally pro-TGFB1 (Fig. 8E) . Similarly, LLC and SLC were detected by anti-LAP in the Itgb8 MO and control MO groups (Fig. 8F) . We did not observe any nonspecific binding with rabbit-anti-goat IgG (HRP-conjugated secondary antibody) (Fig. 8G) .
Functional interaction of TGFB1 with ITGB8. Because we observed the regulation of TGFB1 by ITGB8, we wanted to know their interaction. To determine this, we performed IP of ITGB8 in the crude plasma membrane protein fraction from all stages of the window/period of embryo implantation. Immunoblotting with TGFB1 on ITGB8 IP samples showed the presence of TGFB1 monomer in all the stages of embryo implantation (Day 4 [1000 h] to Day 5 [1000 h]; Fig. 9A ). Specific binding of primary antibody (TGFB1) was confirmed by probing the immunoblot consisting of samples of Day 5 (1000 h) rabbit IgG and recombinant human TGFB1 protein (Fig. 9B) . Furthermore, we validated the specificity of the secondary antibody by immunoblotting with it on blot of Day 4 (1000 h) IP sample (Fig. 9C) . ITGB8 IP confirmation was also done by immunoblotting with ITGB8 antibody. We found ITGB8 in all stages of the embryo implantation period (Fig.  9D) . These results confirmed the interaction between uterine TGFB1 and ITGB8 during embryo implantation. To confirm the specificity of ITGB8 antibody, we probed the IP sample of ITGB8 (Day 4 1000 h stage) with secondary antibody alone (Fig. 9E ) and found no other protein band, except the 50-kDa heavy IgG chain band, which confirmed the specificity of primary antibody (anti-TGFB1 and anti-ITGB8). Furthermore, we cross-checked the physical interaction of ITGB8 with TGFB1 by immunoprecipitating TGFB1 and probing the blot of TGFB immunoprecipiates with the ITGB8 antibody. We found the ITGB8 immunopositive band (;90 kDa) in all the stages of embryo implantation (Fig. 9F) . Similar to ITB8, we also confirmed the presence of TGFB1 in all stages of the embryo implantation period (Fig. 9G) . The anti-TGFB1 showed ;15 kDa (monomer) and ;25 kDa (homodimer) bands on the immunoblot (Fig. 9G) .
Bioneutrilization and knockdown effect of ITGB8 on TGFB1 downstream signaling molecule SMAD2/3. We evaluated the expression level of TGFB1 downstream signaling molecule, SMAD2/3, and active (phosphorylated [p]) SMAD2/ 3 in the anti-ITGB8 IgG-and MO-treated uterine groups. Expression level of total SMAD2/3 did not show a significant difference in the cytosolic and nuclear subcellular fractions between the respective groups (Fig. 10, A, B, E, and F) . The expression level of pSMAD2/3 decreased in the cytosolic fraction of the ITGB8 IgG uterine group compared with that of normal rabbit IgG (P , 0.05 and P , 0.05; Fig. 10, C and D) . Similarly, the nuclear level of pSMAD2/3 was observed to be low in the ITGB8 IgG group compared with that of the control IgG group (P , 0.01 and P , 0.05; Fig. 10, G and H) .
Subsequently, we confirmed the expression of these molecules in the Itgb8 MO-and control MO-treated uterine groups (Fig. 11) . These results also revealed a similar pattern of pSMAD2/3 as that found in anti-ITGB8 IgG-and control IgGtreated uterine groups. Phosphorylated SMAD2/3 expression in the cytosolic fraction was down-regulated at implantation sites of the Itgb8 MO group in comparison to the control MO group (P , 0.05 and P , 0.05; Fig. 11, A and B) . Furthermore, pSMAD2/3 showed significant reduction in the nuclear fraction of the Itgb8 MO implantation sites when compared to control MO (P , 0.05; Fig. 11, C and D) .
DISCUSSION
ITGs play a vital role in the embryonic attachment reaction on the receptive endometrium. Earlier findings have described the presence of ITGB8 on the maternal-fetal bridge [14] , but its functional role in embryo implantation has not been explained. Therefore, we explored the detailed mechanism of ITGB8 using the mouse model of pregnancy/embryo implantation. Our results showed up-regulation of ITGB8 in the uterus during peri-and postimplantation stages of the window/period of embryo implantation in the mouse. Furthermore, the uterine tissue-expressed ITGB8 exhibited comparatively elevated expression at the sites of implantation at Day 5 (0500 h) and Day 5 (1000 h) stages, which indicates its involvement in the embryo implantation process. Similarly, analysis of semiquantitative PCR demonstrated elevated transcript levels of Itgb8 during Day 5 (0500 h) and Day 5 (1000 h), particularly at the sites of embryo implantation, which suggests a requirement of the Itgb8 gene during the embryo implantation period in order to facilitate the embryouterine interaction. An immunolocalization study was done on uterine sections to explore ITGB8's possible functions in a cell-specific manner in the endometrium. We observed predominant expression of ITGB8 on endometrial luminal and glandular epithelium. The expression level of ITGB8 was comparatively higher at implantation sites of peri-and postimplantation stages than that of nonimplantation sites. At the peri-implantation stage, when the blastocyst is 3 and Day 5, 1000 h) (n ¼ 3), and this blot was probed with antibody of ITGB8, which showed immunopositive bands of ITGB8 on all the groups (F). Presence of TGFB1 on its IP samples was verified by immunoblotting with TGFB1 (G).
ITGB8 ACTIVATES TGFB1 IN UTERUS
FIG. 10. Expression of SMAD2/3 and pSMAD2/3 in the cytosolic and nuclear subcellular fraction of the ITGB8 antibody group. The analysis of SMAD2/3 was performed in the cytosol þ plasma membrane (A and B) and nuclear protein fractions of the ITGB8 IgG group (E and F). Active or pSMAD2/3 was studied in the cytosol þ plasma membrane (C and D) and nuclear protein compartment of the ITGB8 IgG group (G and H) as well (n ¼ 7). **P , 0.01, *P , 0.05, not significant (NS), P . 0.05. developed, the uterine ITGB8 might be acting as a guide for blastocyst adhesion [5] . This is supported by our present experiment, where inhibition of ITGB8 led to the failure of embryo implantation, either via down-regulation of ITGB3 or failed embryo implantation due to nonfunctional ITGB8 decreasing the level of ITGB3. A previous study has demonstrated that ITGB3 promotes trophectoderm cell migration and attachment to luminal epithelium [5] . Our findings correlate well with earlier reports, and hint at the possible involvement of ITGB8, along with ITGB3 or alone, in blastocyst attachment on the luminal epithelium [34] . Furthermore, ITGB8 was also expressed on embryo during the peri-implantation period, but we could not decipher its functions. Hence, at this level, we can only relate the expression of ITGB8 on blastocyst to its possible attachment on luminal epithelial cells or other unraveled functions in the process of embryo implantation. However, the mechanism of embryonic interaction on the endometrial epithelial cells during the adhesion/attachment process of the embryo through ITGB8 needs to be elaborated, possibly through in vitro or other suitable assays. During postimplantation stage, ITGB8 might have some other functions, as described in earlier findings [13] , where ITGB8 can regulate the vascular development of yolk. However, with the exception of that study, we have little information, and invite further exploration.
To understand the functional role of ITGB8 in the uterus, we bioneutralized the (uterine) ITGB8 during the preimplantation stage, which exhibited a high rate of embryo implantation failure. We observed fewer numbers of implantation sites in the ITGB8 rabbit IgG-treated uterine horn than that of the control (normal rabbit IgG) uterine horn at Day 5   FIG. 11 . Activity of SMAD2/3 in the cytosolic and nuclear fraction in response to Itgb8 MO. The activity of SMAD2/3 was evaluated by determination of its phosphorylated form in the cytosol þ plasma membrane and nuclear subcellular (A and B) protein compartments of Itgb8 MO treated group (C and D) (n ¼ 7). *P , 0.05, not significant (NS), P . 0.05.
(1000 h). Additionally, the morphology and number of embryos were also affected. The number of embryos retrieved from ITGB8 IgG-administered uterus was ;27% lower in comparison to control. The embryos of the anti-ITGB8 group were unhatched and nondistinguishable between blastocoel and ICM in contrast to the embryos of control group, which could be due to unavailability of functional ITGB8 for the embryonic-uterine interaction. This finding hints at an important role of ITGB8 in the receptivity of endometrium for blastocyst implantation.
To further validate the effect of anti-ITGB8 in embryo implantation, we silenced/interfered with Itgb8 mRNA by its anti-sense MO in the uterus at the preimplantation stage, where reduced embryo implantations along with the embryo implantation sites were noted on Day 5 (1000 h). Furthermore, the interference of ITGB8 signaling during embryo implantation might have affected the pregnancy at Day 13 p.c. Moreover, the inhibition of embryonic specific ITGB8 activity might have contributed some negative effect on embryonic development in parallel to the uterine ITGB8, which can hinder communication between embryo and endometrium during the adhesion/ attachment process. It can be inferred from these observations that there might be a parallel effect of blastocyst-expressed ITGB8 on embryonic development as well, but determining how this dialog happens will require further investigation.
Additionally, we observed that the embryo implantation/ uterine receptivity-related molecules, such as ITGB3 and STAT3, were down-regulated when the function or gene expression of Itgb8 was blocked. We also evaluated the transcript level of another implantation marker, Bmp2, and found reduced mRNA levels in ITGB8 antibody-and MOtreated groups. Thus, we can interpret our data to indicate that the blockage of ITGB8 functions and its mRNA downregulation interferes with the responsiveness of receptive endometrium for embryo implantation through ITGB3, BMP2, and STAT3 directly or indirectly. Herein, we postulate that inhibition of ITGB8 led to the blockage of implantation of embryo, either via down-regulation of ITGB3, BMP2, and STAT3, or via failed embryo implantation induced by nonfunctional ITGB8-mediated loss of expression of ITGB3, BMP2, and STAT3.
Furthermore, ECM-ITGs can mediate intracellular signaling cascades that strengthen their adhesive activity [35] . In many cells, TGFB is stored in the ECM as a latent inactive complex, and ITGB8 can activate TGFB1 and, hence, release it from the ECM [11] . TGFB is involved in embryo implantation [17] and it can be regulated by ITGB8 in various cell types [36, 37] . However, the regulation of TGFB1 in the endometrium by ITGB8 is not well documented. TGFB is produced in the cell as an inactive latent complex, associated with the LAP and latent complex of TGFB1 (LTBP-1) [38, 39] , which is released into a biologically active TGFB form (;25 kDa homodimer or ;12-17 kDa monomer) by the action of ITGB8 [11] . Previous findings showed the binding of LAP (a component of latent/ inactive TGFB1) with ITGB8, indicating interaction of LAP and ITGB8 for TGFB1 signaling on uterine epithelium [14] , but could not explain the action of ITGB8 on latent TGFB1. Furthermore, our recent study revealed release of active TGFB1 from its latent complex during the embryo implantation period [17] , and found its association with embryo implantation (implantation sites and decidualization process). Therefore, these findings prompted us to analyze the release/ activation of TGFB from its latent complex in the ITGB8-bioneutralized and MO-inhibited uterine tissues, which exhibited the compromised release of mature or biologically active monomer (;17 kDa) form of TGFB on the immunoblot. Latent TGFB complexes detected by anti-TGFB1 (LLC and SLC) were also observed by LAP immunoblotting, confirming interaction between TGFB1 and LAP. Moreover, the activity/ phosphorylation of SMAD2/3, downstream messenger of active TGFB, was noted to be down-regulated, which was similar to the level of the active form of TGFB (;17-kDa monomer) in the ITGB8-bionetralized uterus. Evidently, the down-regulated pSMAD2/3 in the ITGB8-bioneutralized and MO-inhibited uterine tissues is due to inhibition of TGFB activation [17] . Additionally, we found the presence of ITGB8 and TGFB1 in immunoprecipitated samples for both of the proteins. This confirmed that ITGB8 can interact functionally as well as physically with TGFB (either alone or with latent KUMAR ET AL. complex). Hence, our present study confirms that ITGB8 and TGFB1 can interact functionally during the process of embryo implantation.
Taken together, our results show that ITGB8 is required for the embryo implantation process, and can functionally interact with TGFB1 to activate it from the LTBP and LAP-b complex in the endometrium (Fig. 12) . Thus, the locally (maternal) available TGFB1 appears to be regulated and released into the uterus through ITGB8 during embryo implantation (Fig. 12) ; however, other contributing factors that might also regulate the activation of TGFB1 cannot be ruled out. In conclusion, our present study is important for establishing the proof of principle that ITGB8 can regulate embryo implantation via control of TGFB1 signaling.
